From: A convolutional neural network-based system to classify patients using FDG PET/CT examinations
 | n (%) |
---|---|
Total patients | 3485 |
 Males | 1954 (56.1) |
 Females | 1531 (43.9) |
Age (in years) | |
 Mean ± SD | 63.9 ± 13.6 |
 Range | 24–95 |
Cancer-related biomarkers | Positive/Total (%) |
 AFP | 16/167 (9.6) |
 CA19–9 | 177/591 (29.9) |
 CEA | 282/889 (31.7) |
 CYFRA | 138/402 (34.3) |
 NSE | 381/621 (61.4) |
 PIVKA-II | 24/135 (17.8) |
 Pro-GRP | 95/540 (17.6) |
 PSA | 18/55 (32.7) |
 SCC | 172/784 (21.9) |
 S-hCG | 3/3 (100) |
Pretest diagnosis | n (%) |
 Head and neck neoplasms | 988 (28.4) |
 Hematopoietic neoplasms | 510 (14.6) |
 Neoplasms of lung, pleura, or mediastinum | 507 (14.5) |
 Hepatobiliary neoplasms | 305 (8.8) |
 Gastrointestinal neoplasms | 258 (7.4) |
 Skin neoplasms | 168 (4.8) |
 Urologic neoplasms | 135 (3.9) |
 Gynecological neoplasms | 112 (3.2) |
 Sarcoidosis | 91 (2.6) |
 Breast neoplasms | 67 (1.9) |
 Brain and spinal neoplasms | 65 (1.9) |
 Others | 279 (8.0) |